Publications by authors named "S Kiyono"
Cytokine release syndrome (CRS) is a systemic inflammatory syndrome that causes fatal circulatory failure due to hypercytokinemia, and subsequent immune cell hyperactivation caused by therapeutic agents, pathogens, cancers, and autoimmune diseases. In recent years, CRS has emerged as a rare, but significant, immune-related adverse event linked to immune checkpoint inhibitor therapy. Furthermore, several previous studies suggested that damage-associated molecular patterns (DAMPs) could be involved in malignancy-related CRS.
View Article and Find Full Text PDFArticle Synopsis
- This study assessed the safety and effectiveness of ramucirumab as a second- and third-line treatment for advanced hepatocellular carcinoma (HCC) in a real-world setting, complementing findings from the REACH-2 trial.
- Conducted in Japan with 19 enrolled patients, the study found a 6-month progression-free survival rate of 14.3%, with median progression-free survival and overall survival of 3.7 and 12.0 months, respectively.
- The most common severe adverse events included hypertension (23.5%), proteinuria (17.6%), and neutropenia (11.8%), with 29.4% of patients discontinuing treatment due to these adverse effects.
Background: During systemic therapy, the management of portal hypertension (PH)-related complications is vital. This study aimed to clarify factors associated with the incidence and exacerbation of PH-related complications, including the usefulness of contrast-enhanced computed tomography (CECT) in the management of PH-related complications during systemic therapy.
Methods: A total of 669 patients who received systemic therapy as first-line treatment (443 patients for sorafenib, 131 for lenvatinib, and 90 for atezolizumab/bevacizumab [ATZ/BEV]) were enrolled in this retrospective study.
Purpose: This study aimed to investigate the safety and efficacy of lenvatinib in real-world settings, including patients excluded from the REFLECT trial, a phase III trial that compared lenvatinib with sorafenib.
Patients And Methods: This multicenter, nonrandomized, open-label prospective study was conducted at 10 medical facilities in Japan (jRCTs031190017). Eligible patients had advanced hepatocellular carcinoma (HCC) and were suitable for lenvatinib therapy.
The pathogenesis of acute liver failure (ALF) involves cell death. Necroptosis is a newly suggested programmed cell death, and receptor-interacting protein kinase 3 (RIPK3) has been reported as a marker for necroptosis. However, there are few reports on necroptosis in ALF.
View Article and Find Full Text PDF